Published in Am J Health Syst Pharm on March 15, 2007
Antibodies against glucan, chitin, and Saccharomyces cerevisiae mannan as new biomarkers of Candida albicans infection that complement tests based on C. albicans mannan. Clin Vaccine Immunol (2008) 0.88
Economic evaluation of caspofungin vs liposomal amphotericin B for empirical therapy of suspected systemic fungal infection in the German hospital setting. Ann Hematol (2007) 0.84
Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin and its impact on use and costs: review of the literature. Eur J Med Res (2011) 0.81
Pharmacoeconomic evaluation of voriconazole vs. liposomal amphotericin B in empiric treatment of invasive fungal infections in Turkey. BMC Infect Dis (2013) 0.77
Pharmacoeconomic analysis of antifungal therapy for primary treatment of invasive candidiasis caused by Candida albicans and non-albicans Candida species. BMC Infect Dis (2017) 0.75
Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med (2004) 8.11
Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health (2004) 4.98
Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med (2004) 3.93
Osteoporosis and fracture risk in women of different ethnic groups. J Bone Miner Res (2004) 3.37
A metaanalysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs. J Rheumatol (2002) 2.54
GRACE principles: recognizing high-quality observational studies of comparative effectiveness. Am J Manag Care (2010) 1.98
Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood (2010) 1.97
Stanford presenteeism scale: health status and employee productivity. J Occup Environ Med (2002) 1.74
The assessment of chronic health conditions on work performance, absence, and total economic impact for employers. J Occup Environ Med (2005) 1.67
A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med (2002) 1.61
Prediction of fracture risk in postmenopausal white women with peripheral bone densitometry: evidence from the National Osteoporosis Risk Assessment. J Bone Miner Res (2002) 1.58
Antihypertensive persistence and drug class. Can J Cardiol (2002) 1.48
Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report--Part II. Value Health (2009) 1.43
Measuring the effects of work loss on productivity with team production. Health Econ (2006) 1.31
Costs and survival of patients with colorectal cancer in a health maintenance organization and a preferred provider organization. Med Care (2005) 1.31
A general model of the impact of absenteeism on employers and employees. Health Econ (2002) 1.31
Variation in average costs among federally sponsored state-organized cancer detection programs: economies of scale? Med Decis Making (2002) 1.28
Comparative effectiveness: asking the right questions, choosing the right method. Health Aff (Millwood) (2005) 1.25
Valuing reductions in on-the-job illness: 'presenteeism' from managerial and economic perspectives. Health Econ (2008) 1.24
The impact of consumer-directed health plans on prescription drug use. Health Aff (Millwood) (2008) 1.23
Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I. Value Health (2009) 1.22
Impact of 3-tier pharmacy benefit design and increased consumer cost-sharing on drug utilization. Am J Manag Care (2005) 1.19
Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients. J Clin Microbiol (2007) 1.18
Use of bronchoalveolar lavage to detect galactomannan for diagnosis of pulmonary aspergillosis among nonimmunocompromised hosts. J Clin Microbiol (2007) 1.17
Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation. Diabetes Care (2003) 1.12
Frequency of potential azole drug-drug interactions and consequences of potential fluconazole drug interactions. Pharmacoepidemiol Drug Saf (2005) 1.11
Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries. Clin Infect Dis (2006) 1.05
How to present the business case for healthcare quality to employers. Appl Health Econ Health Policy (2005) 1.04
The National Program of Cancer Registries: explaining state variations in average cost per case reported. Prev Chronic Dis (2005) 1.02
Reliability and validity of the Stanford Presenteeism Scale. J Occup Environ Med (2004) 1.02
Colorectal cancer screening attitudes and practices in the general population: a risk-adjusted survey. J Public Health Manag Pract (2005) 1.00
Invasive candidiasis treated in the intensive care unit: observations from a randomized clinical trial. J Crit Care (2007) 0.97
Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study. Menopause (2003) 0.95
A randomized controlled open trial of population-based disease and case management in a Medicare Plus Choice health maintenance organization. Prev Chronic Dis (2004) 0.93
Meta-analysis of dyspepsia and nonsteroidal antiinflammatory drugs. Arthritis Rheum (2003) 0.92
Burden of hospitalization of patients with Candida and Aspergillus infections in Australia. Int J Infect Dis (2004) 0.91
Do NSAIDs cause dyspepsia? A meta-analysis evaluating alternative dyspepsia definitions. Am J Gastroenterol (2002) 0.89
Aligning quality for populations and patients: do we know which way to go? Am J Public Health (2003) 0.89
Raising the bar of efficacy for drug approval requires an understanding of patient diversity. J Clin Oncol (2010) 0.86
Response and relapse rates of candidal esophagitis in HIV-infected patients treated with caspofungin. AIDS Res Hum Retroviruses (2002) 0.86
Overview of safety experience with caspofungin in clinical trials conducted over the first 15 years: a brief report. Int J Antimicrob Agents (2011) 0.86
Asthma control and patient satisfaction among early pediatric users of montelukast. J Asthma (2002) 0.85
The role of private industry in pragmatic comparative effectiveness trials. J Comp Eff Res (2012) 0.85
Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies. Biol Blood Marrow Transplant (2004) 0.84
Busulfan, cyclophosphamide, and etoposide as conditioning for autologous stem cell transplantation in multiple myeloma. Am J Hematol (2003) 0.84
Treatment of migraine with rizatriptan: when to take the medication. Headache (2002) 0.83
Getting real performance out of pay-for-performance. Milbank Q (2008) 0.81
Caspofungin versus amphotericin B for candidemia: a pharmacoeconomic analysis. Clin Ther (2005) 0.81
Caspofungin use in patients with invasive candidiasis caused by common non-albicans Candida species: review of the caspofungin database. Antimicrob Agents Chemother (2010) 0.80
Does initial choice of antimicrobial therapy affect length of stay for patients with complicated intra-abdominal infections? Am Surg (2005) 0.80
Endogeneity bias in the absence of unobserved heterogeneity. Ann Epidemiol (2004) 0.79
Do disease management programs for patients with coronary heart disease make a difference? Experiences of nine practices. Am J Manag Care (2002) 0.79
The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathy. Pharmacoeconomics (2006) 0.78
Growth in use of lipid-lowering therapies: are we targeting the right patients? Am J Manag Care (2002) 0.77
Impact of migraine symptoms on health care use and work loss in Canada in patients randomly assigned in a phase III clinical trial. Can J Clin Pharmacol (2002) 0.77
Efficacy and safety of caspofungin in obese patients. Med Mycol (2011) 0.77
Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective. Can J Cardiol (2004) 0.76
Utilization of Positive and Negative Controls to Examine Comorbid Associations in Observational Database Studies. Med Care (2016) 0.75
Evidence synthesis and evidence-based decision making: related but distinct processes. Med Decis Making (2005) 0.75
Misaligned incentives in America's health: who's minding the store? Ann Fam Med (2005) 0.75
The decision to conduct a head-to-head comparative trial: a game-theoretic analysis. Med Decis Making (2007) 0.75
Rational formulary decision making: is drug classification rational? Value Health (2003) 0.75
The view of a model user on the ISPOR-SMDM modeling good research task force report. Value Health (2012) 0.75
Treatment outcomes in patients receiving conventional amphotericin B therapy: a prospective multicentre study in Taiwan. J Antimicrob Chemother (2006) 0.75